<p>Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on A Comparison of Outcomes With Apixaban, Rivaroxaban, and Warfarin for Atrial Fibrillation and/or Venous Thromboembolism.</p>

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on A Comparison of Outcomes With Apixaban, Rivaroxaban, and Warfarin for Atrial Fibrillation and/or Venous Thromboembolism.

A Comparison of Outcomes With Apixaban, Rivaroxaban, and Warfarin for Atrial Fibrillation and/or Venous Thromboembolism | JACC: Advances

In this podcast series, editors-in-chief from the JACC family of specialty journals provide highlights and summarize key findings for select issues. Published by the American College of Cardiology, the JACC Journals publish peer-reviewed articles on all aspects of cardiovascular disease, including original clinical studies, translational investigations with clear clinical relevance, state-of-the art papers, and review articles. They are top ranked for impact factor and their manuscripts are among the most covered by media outlets, most talked about on social media, and most read online.

Share A Comparison of Outcomes With Apixaban, Rivaroxaban, and Warfarin for Atrial Fibrillation and/or Venous Thromboembolism | JACC: Advances

Sign up to save your podcasts

A Comparison of Outcomes With Apixaban, Rivaroxaban, and Warfarin for Atrial Fibrillation and/or Venous Thromboembolism | JACC: Advances

A Comparison of Outcomes With Apixaban, Rivaroxaban, and Warfarin for Atrial Fibrillation and/or Venous Thromboembolism | JACC: Advances